Feb 26, 2024 · ... CAR-T therapies, and biologics in oncology and immunology. ... At Galapagos, we organize clinical trials in ... More about our company, science and people. We ...

Dec 9, 2023 · “We are very pleased to share promising new data from our ongoing CD19 CAR-T cell therapy programs, which further highlight that treatment with both GLPG5201 ...

Feb 23, 2024 · Galapagos used its earnings report to disclose that work has been halted on a CD19 CAR-T candidate for refractory systemic lupus erythematosus.

5 days ago · Galapagos said the collaboration could help overcome the limitations that have held back access to CAR-T therapies from other companies.

Nov 7, 2023 · Landmark Bio and Galapagos have signed an agreement for the manufacture of the latter's oncology CAR T-cell therapy.

Dec 29, 2023 · CAR T-therapy can treat advanced cases of blood cancer, but an ongoing challenge is logistics. The work turning a patient's own immune cells into a cell ...

Nov 6, 2023 · Landmark Bio will serve as strategic point-of-care manufacturing partner for Galapagos' CAR-T product candidates in the Boston area. WATERTOWN, Mass., Nov.

Feb 23, 2024 · News Reporter. Galapagos has stopped developing its CD19 CAR-T candidate in autoimmune diseases, including plans for a trial in systemic lupus erythematosus, ...

Nov 10, 2023 · miDiagnostics announces collaboration with Galapagos to develop closed-flow, ultra-rapid CAR-T sterility test for its point-of-care CAR-T manufacturing platform.

Nov 2, 2023 · Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5101) in Relapsed/Refractory NHL: Results from the Phase 1 Atalanta-1 Trial. Marie José ...